Patent intelligence · US
US 11744800
Methods of use of emulsion formulations of an NK-1 receptor antagonist
Methods of use of emulsion formulations of an NK-1 receptor antagonist
Patent details — US 11744800
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 5, 2023
- Expiration
- Aug 31, 2043
- Applicant
- Heron Therapeutics, Inc.
- Claims
- 30
- CPC classes
- A61K, A61K31/43, A61K31/435, A61K31/496
Quick answer
US 11744800 (Methods of use of emulsion formulations of an NK-1 receptor antagonist) is held by Heron Therapeutics, Inc.. Status: granted. Granted Sep 5, 2023. Expires Aug 31, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Heron Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 30
- CPC classes
- A61K, A61K31/43, A61K31/435, A61K31/496, A61K31/5377, A61K31/573
More from Heron Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12318376
Compositions of a polyorthoester and an aprotic solvent
granted -
US 12290520
Methods of use of emulsion formulations of aprepitant
granted -
US 12115254
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 12115255
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 11878074
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 11844837
Compositions of a polyorthoester and an organic acid excipient
granted -
US 11413350
Long-acting polymeric delivery systems
granted
Frequently asked questions
What is US patent 11744800?
US 11744800 (Methods of use of emulsion formulations of an NK-1 receptor antagonist) is held by Heron Therapeutics, Inc.. Status: granted. Granted Sep 5, 2023. Expires Aug 31, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11744800?
Heron Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 46 pharmaceutical patents for this assignee.
When does US 11744800 expire?
Our index shows an expiration date of Aug 31, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.